Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Earnings Data
Report Date
Nov 10, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.53Last Year’s EPS
0.08Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant growth in test volumes and successful collaborations, but also highlighted challenges in dermatological test revenues and reimbursement issues. Despite these challenges, Castle Biosciences raised its revenue guidance for the year, indicating optimism about future growth.Company Guidance
Strong Revenue and Test Volume Growth
Castle Biosciences reported revenue of $86.2 million with a total test report volume of 26,574, representing a 33% year-over-year growth for core revenue drivers compared to Q2 2024.
DecisionDx-Melanoma Test Success
The DecisionDx-Melanoma test saw a sequential increase of approximately 16% compared to Q1 2025 and a year-over-year increase of 4%. The test was associated with a 32% reduction in mortality risk in a real-world cohort.
Significant Growth in TissueCypher Test
TissueCypher test reports increased to 9,170 in Q2 2025 from 4,782 in Q2 2024, marking a 92% year-over-year growth.
Strong Financial Position
Castle ended the quarter with $275.9 million in cash, cash equivalents, and marketable securities, supporting continued investment in growth initiatives.
Raised Revenue Guidance
For total revenue in 2025, guidance was raised to $310 million to $320 million, up from the previous range of $287 million to $297 million.
Successful Collaborations and Pipeline Developments
Castle entered into a collaboration with SciBase and reported success in its internally developed atopic dermatitis test, expected to launch by the end of 2025.
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 04, 2025 | $15.32 | $20.35 | +32.83% |
May 05, 2025 | $18.75 | $16.62 | -11.36% |
Feb 27, 2025 | $25.28 | $21.68 | -14.24% |
Nov 04, 2024 | $33.64 | $31.15 | -7.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at Nov 10, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2025 (Q3) is -0.53.